Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | XBP1 | P17861 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15532876 | 0.91 | CNR1 (0.63) | CNR1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL6789878 | 0.86 | MEN1 (0.51) | CNR1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL23456343 | 0.85 | MEN1 (0.74) | CNR1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL136432 | 0.84 | MEN1 (0.72) | CNR1MEN1KMT2AMAPTHTT | |
| SCHEMBL30831949 | 0.84 | CNR1 (0.67) | CNR1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL14873812 | 0.83 | KMT2A (0.61) | CNR1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL9938209 | 0.83 | CNR1 (0.60) | CNR1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL9280415 | 0.83 | CNR1 (0.60) | CNR1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL9936949 | 0.83 | CNR1 (0.60) | CNR1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL4638830 | 0.82 | CNR1 (0.47) | CNR1RAB9AMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114152-B2 | Stent coating | ICON INTERVENTIONAL SYSTEMS, INC. (US) | 2012-02-14 | — | — | US | claimed |
| US-20210163404-A1 | NOVEL UREA COMPOUNDS AND BIOISOSTERES THEREOF AND THEIR USE FOR TREATING INFLAMMATION AND INFLAMMATION-RELATED PATHOLOGIES | UNIVERSITé LAVAL (CA) | 2021-06-03 | — | — | US | disclosed |
| US-20130102657-A1 | ANTI-ANGIOGENIC COMPOSITIONS AND METHODS OF USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-04-25 | — | — | US | disclosed |
| US-8221794-B2 | Anti-angiogenic nanoparticle compositions | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2012-07-17 | — | — | US | disclosed |
| US-8114152-B2 | Stent coating | ICON INTERVENTIONAL SYSTEMS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110118825-A1 | ANTI-ANGIOGENIC COMPOSITIONS AND METHODS OF USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2011-05-19 | — | — | US | disclosed |
| US-20110071612-A1 | ANTI-ANGIOGENIC COMPOSITIONS AND METHODS OF USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2011-03-24 | — | — | US | disclosed |
| US-20110066251-A1 | ANTI-ANGIOGENIC COMPOSITIONS AND METHODS OF USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2011-03-17 | — | — | US | disclosed |
| US-20100292314-A1 | ANTI-ANGIOGENIC COMPOSITIONS AND METHODS OF USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2010-11-18 | — | — | US | disclosed |
| US-7820193-B2 | Anticancer agents; prevent forming blood vessels; removal blockage | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2010-10-26 | — | — | US | disclosed |
| US-5716981-A | A STENT COATED WITH PACLITAXEL, A TAXAN DERIVATIVE AND A POLYMERIC CARRIER; MEDICAL EQUIPMENT FOR DEBLOCKING | ANGIOGENESIS TECHNOLOGIES, INC. (CA) | 1998-02-10 | — | — | US | disclosed |
| EP-0766675-A4 | IMPROVED CHICHIBABIN AMINATIONS OF PYRIDINE BASES | REILLY IND INC (US) | 1997-09-24 | — | — | EP | disclosed |
| EP-0766675-A1 | IMPROVED CHICHIBABIN AMINATIONS OF PYRIDINE BASES | REILLY INDUSTRIES, INC. (US) | 1997-04-09 | — | — | EP | disclosed |
| WO-1996000216-A1 | IMPROVED CHICHIBABIN AMINATIONS OF PYRIDINE BASES | REILLY INDUSTRIES, INC. (US) | 1996-01-04 | — | — | WO | disclosed |
| US-5003069-A | Chichibabin reaction | REILLY INDUSTRIES, INC. (US) | 1991-03-26 | — | — | US | disclosed |
| EP-0091790-B1 | PROCESS FOR PREPARING 2-ALKYLAMINO- AND 2-AMINO-5-ALKYLPYRIDINES | REILLY INDUSTRIES, INC. (US) | 1989-11-15 | — | — | EP | disclosed |
| EP-0098684-A2 | Modified chichibabin reaction, and novel pyridine derivatives | REILLY INDUSTRIES, INC. (US) | 1984-01-18 | — | — | EP | disclosed |
| EP-0091790-A2 | Process for preparing 2-alkylamino- and 2-amino-5-alkylpyridines | REILLY INDUSTRIES, INC. (US) | 1983-10-19 | — | — | EP | disclosed |
| US-4405790-A | FROM 3-ALKYLPYRIDINE; SODIUM ALKYLAMIDE | REILLY TAR & CHEMICAL CORP. (US) | 1983-09-20 | — | — | US | disclosed |
| US-4386209-A | Chichibabin reaction | REILLY TAR & CHEMICAL CORPORATION (US) | 1983-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163404-A1 | NOVEL UREA COMPOUNDS AND BIOISOSTERES THEREOF AND THEIR USE FOR TREATING INFLAMMATION AND INFLAMMATION-RELATED PATHOLOGIES | NOS3, NOS2, CBS | CNR1 1227/4885RAB9A 2066/4885MEN1 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.